The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1387
Low-Dose Sublingual Zolpidem (Intermezzo) for Insomnia due to Middle-of-the-Night Awakening
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a new low-dose sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem tartrate (Intermezzo – Transcept/Purdue) for treatment of insomnia due to middle-of-the-night awakening. Ambien and other zolpidem formulations available in the US are labeled for use only at bedtime.

PHARMACOKINETICS — A daytime study in 24 normal volunteers found that within 20 minutes after administration, both doses (1.75 and 3.5 mg) of the new formulation produced plasma concentrations >20 ng/mL, the level associated with sedation, and maintained that level for up to 4 hours. Serum concentrations reached a maximum in 37 minutes (Tmax). The half-life was 2.4 hours, and at 12 hours the drug was no longer detectable in plasma.1 According to the manufacturer, peak serum concentrations (Cmax) and the area under the time-concentration curve (AUC) are ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Low-Dose Sublingual Zolpidem (Intermezzo) for Insomnia due to Middle-of-the-Night Awakening
Article code: 1387a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian